Inmed Pharmaceuticals Inc. (IMLFF) 0.1950 $IMLFF
InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com
Newsfile Corp - Wed May 13, 10:32AM CDT
full story)
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
Marketwired - Tue May 12, 11:45AM CDT
InMed Pharmaceuticals Inc. ("InMed" or the "Company"
(CSE: IN)(OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of eye diseases.
CARERS Act Likely to Intensify Awareness for DUI Laws and Need for Marijuana Breathalyzer
ACCESSWIRE - Wed May 06, 7:01AM CDT
WHITFISH, MT / ACCESSWIRE / May 6, 2015 / The marijuana industry received some substantial news in March with bi-partisan support in both chambers of Congress that would facilitate growth for the industry by loosening federal marijuana laws. Rep. Steve Cohen (D-TN) with co-sponsor Rep. Don Young (R-AK) filed the House version of the CARERS Act (short for Compassionate Access, Research Expansion, and Respect States) and six additional House members co-sponsoring the bill have now joined them. The Senate version, filed by Senators Cory Booker (D-NJ), Rand Paul (R-KY), and Kirsten Gillibrand (D-NY) earlier in the month has added two additional senators as co-sponsors. The CARERS Act aims to resolve several problematic regulations with marijuana, including allowing interstate commerce, opening the banking system to marijuana dispensaries, permitting the Veterans Administration to recommend medical marijuana to vets, rescheduling marijuana to Schedule 2, allowing states to legalize marijuana for medical use without federal interference and eliminate barriers to medical marijuana research. If passed into law, it will benefit a wide array of marijuana companies, including cannabinoid-based drug developers like GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY) and InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN).
INSY: 59.00 (+0.17), GWPH: 112.25 (-0.07), ABBV: 65.99 (+0.02)
InMed Engages Peter Mountford as Strategic Advisor
PR Newswire - Tue May 05, 3:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced today that former GW Pharmaceuticals financier, investor, and Non-Executive Director, Peter Mountford, has agreed to support InMed as Strategic Advisor with primary responsibility for the European markets.
InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.
PR Newswire - Thu Apr 30, 10:00AM CDT
InMed Pharmaceuticals, Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced it is now eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC" to facilitate electronic settlement of transfers of its common shares in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT
INSY: 59.00 (+0.17)
InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy
Marketwired - Wed Apr 15, 5:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabinoid-based therapies, today announced that it has been awarded a grant to further develop the Company's proprietary nanoparticle-based delivery system for their leading drug candidate CTI-085 for glaucoma. Initial formulation, in vitro & in vivo development is currently underway in collaboration with members of the Department of Chemical & Biological Engineering at the University of British Columbia. The grant from Mitacs, a leading Canadian non-profit organization that accelerates innovative projects through strategic academic and industry collaboration, is partially funding the ongoing development of the delivery system and is the second grant awarded to InMed from Mitacs.
InMed Pharmaceuticals Strengthens Scientific Advisory Board
PR Newswire - Tue Mar 31, 7:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced the appointment of Paul C. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed.
InMed Receives Exemption Status from Health Canada
Marketwired - Mon Mar 23, 7:02AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2015, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act.
2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 48.95 (-0.42), GFI: 3.84 (-0.02), BIS: 31.35 (-0.07), ACH: 16.33 (-0.21), BOI: 16.16 (-0.03)
InMed Initiates Discovery & Pre-clinical Work on Orofacial Pain
Marketwired - Wed Mar 18, 10:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic orofacial pain. Initial drug discovery and preclinical development is currently underway in collaboration with members of the Faculty of Pharmaceutical Sciences at the University of British Columbia. The work is being funded by a grant from Mitacs, a leading Canadian organization that accelerates innovative projects through strategic academic and industry collaboration.
InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies
PR Newswire - Tue Mar 10, 10:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN; OTCQB: IMLFF) announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and will be led by one of the world's leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases.
48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 112.25 (-0.07)
InMed Pharmaceuticals to Present Investor Webcast March 5
CNW Group - Mon Mar 02, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time presentation at VirtualInvestorConferences.com
InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com
Newsfile Corp - Wed May 13, 10:32AM CDT
full story)
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
Marketwired - Tue May 12, 11:45AM CDT
InMed Pharmaceuticals Inc. ("InMed" or the "Company"
(CSE: IN)(OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of eye diseases. CARERS Act Likely to Intensify Awareness for DUI Laws and Need for Marijuana Breathalyzer
ACCESSWIRE - Wed May 06, 7:01AM CDT
WHITFISH, MT / ACCESSWIRE / May 6, 2015 / The marijuana industry received some substantial news in March with bi-partisan support in both chambers of Congress that would facilitate growth for the industry by loosening federal marijuana laws. Rep. Steve Cohen (D-TN) with co-sponsor Rep. Don Young (R-AK) filed the House version of the CARERS Act (short for Compassionate Access, Research Expansion, and Respect States) and six additional House members co-sponsoring the bill have now joined them. The Senate version, filed by Senators Cory Booker (D-NJ), Rand Paul (R-KY), and Kirsten Gillibrand (D-NY) earlier in the month has added two additional senators as co-sponsors. The CARERS Act aims to resolve several problematic regulations with marijuana, including allowing interstate commerce, opening the banking system to marijuana dispensaries, permitting the Veterans Administration to recommend medical marijuana to vets, rescheduling marijuana to Schedule 2, allowing states to legalize marijuana for medical use without federal interference and eliminate barriers to medical marijuana research. If passed into law, it will benefit a wide array of marijuana companies, including cannabinoid-based drug developers like GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY) and InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN).
INSY: 59.00 (+0.17), GWPH: 112.25 (-0.07), ABBV: 65.99 (+0.02)
InMed Engages Peter Mountford as Strategic Advisor
PR Newswire - Tue May 05, 3:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced today that former GW Pharmaceuticals financier, investor, and Non-Executive Director, Peter Mountford, has agreed to support InMed as Strategic Advisor with primary responsibility for the European markets. InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.
PR Newswire - Thu Apr 30, 10:00AM CDT
InMed Pharmaceuticals, Inc. ("InMed"
(CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced it is now eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC" to facilitate electronic settlement of transfers of its common shares in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors. Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT
INSY: 59.00 (+0.17)
InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy
Marketwired - Wed Apr 15, 5:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabinoid-based therapies, today announced that it has been awarded a grant to further develop the Company's proprietary nanoparticle-based delivery system for their leading drug candidate CTI-085 for glaucoma. Initial formulation, in vitro & in vivo development is currently underway in collaboration with members of the Department of Chemical & Biological Engineering at the University of British Columbia. The grant from Mitacs, a leading Canadian non-profit organization that accelerates innovative projects through strategic academic and industry collaboration, is partially funding the ongoing development of the delivery system and is the second grant awarded to InMed from Mitacs. InMed Pharmaceuticals Strengthens Scientific Advisory Board
PR Newswire - Tue Mar 31, 7:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced the appointment of Paul C. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed. InMed Receives Exemption Status from Health Canada
Marketwired - Mon Mar 23, 7:02AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2015, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act. 2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 48.95 (-0.42), GFI: 3.84 (-0.02), BIS: 31.35 (-0.07), ACH: 16.33 (-0.21), BOI: 16.16 (-0.03)
InMed Initiates Discovery & Pre-clinical Work on Orofacial Pain
Marketwired - Wed Mar 18, 10:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic orofacial pain. Initial drug discovery and preclinical development is currently underway in collaboration with members of the Faculty of Pharmaceutical Sciences at the University of British Columbia. The work is being funded by a grant from Mitacs, a leading Canadian organization that accelerates innovative projects through strategic academic and industry collaboration. InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies
PR Newswire - Tue Mar 10, 10:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN; OTCQB: IMLFF) announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and will be led by one of the world's leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases. 48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 112.25 (-0.07)
InMed Pharmaceuticals to Present Investor Webcast March 5
CNW Group - Mon Mar 02, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time presentation at VirtualInvestorConferences.com
